Surgical risk evaluation of lung cancer in COPD patients – A cohort observational study  by Rodrigues, F. et al.
RO
S
p
F
a
b
c
d
e
R
A
L
h
2
Bev Port Pneumol. 2016;22(5):266--272
www.revportpneumol.org
RIGINAL ARTICLE
urgical  risk  evaluation  of  lung cancer  in COPD
atients --  A cohort  observational  study
. Rodriguesa,b,∗, M. Graﬁnoa, I. Fariaa, J. Pontes da Mataa, A.L. Papoilac,d, F. Félixe
Servic¸o  de  Pneumologia,  Hospital  Pulido  Valente,  Centro  Hospitalar  Lisboa  Norte,  Portugal
Faculdade  de  Medicina,  Universidade  de  Lisboa,  Portugal
NOVA  Medical  School/Faculdade  de  Ciências  Médicas,  Universidade  Nova  de  Lisboa,  Portugal
Centro  de  Estatística  e  Aplicac¸ões  da  Universidade  de  Lisboa,  Portugal
Servic¸o  de  Cirurgia  Torácica,  Hospital  Pulido  Valente,  Centro  Hospitalar  Lisboa  Norte,  Portugal
eceived  4  December  2015;  accepted  29  February  2016
vailable  online  9  May  2016
KEYWORDS
Chronic  obstructive
pulmonary  disease;
Lung  cancer;
Cardiopulmonary
exercise  testing;
Postoperative
complications
Abstract  Coexistence  between  pulmonary  cancer  and  chronic  obstructive  pulmonary  disease
(COPD) is  frequent  and  is  anticipated  to  be  lead  to  high  worldwide  mortality  in  the  next  decades.
The most  powerful  therapeutic  approach  for  non-small  cell  lung  carcinoma  is  lung  surgical
resection.  However,  in  COPD  patients,  this  approach  bears  a  higher  mortality  and  morbidity  risk,
thus requiring  an  accurate  pre-operatory  evaluation  of  the  surgical  risk  comprising  a  clinical
and functional  assessment  at  rest,  as  well  as  a  cardiopulmonary  exercise  test.  In  this  observa-
tional study,  factors  associated  with  cardiopulmonary  complications  within  30  days  after  tumor
resection surgery  were  investigated  in  a  cohort  of  patients  with  COPD  and  lung  cancer  assigned
to perform  a  cardiopulmonary  exercise  test.
This study  included  50  patients  (46  men,  92.0%)  with  a  mean  age  of  64.7  years  old  (standard
deviation  7.9),  forced  expiratory  volume  in  the  ﬁrst  second  (FEV1)  of  61.8%  (SD  19.0%)  and
carbon monoxide  diffusing  capacity  (DLCO)  of  46.0%  (SD  14.8%).
Complications  were  observed  in  eighteen  patients  (36.0%)  including  2  deaths  (4.0%).  Peak
oxygen uptake  (VO2peak)  expressed  in  percentage  of  the  predicted  value  was  the  only  parameter
showing a  statistically  signiﬁcant  difference  between  the  groups  with  and  without  complications
(p =  0.027).  The  best  value  of  VO2peak to  discriminate  complications  occurrence  was  61.0%.
This study  highlights  the  relevance  of  the  cardiopulmonary  exercise  test  in  the  risk  assessment
of pulmonary  resection  surgery  in  patients  with  COPD.  The  VO2peak (percentage  of  predicted
value) is  shown  to  be  associated  with  complications  within  30  days  after  surgery.
© 2016  Sociedade  Portuguesa  de  Pneumologia.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is  an
open access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-
nc-nd/4.0/). This study was carried out at the Servic¸o de Pneumologia and Servic¸o
inhas de Torres, 117 1769-001 Lisbon, Portugal.
∗ Corresponding author.
E-mail address: fatima.rodriguesed@gmail.com (F. Rodrigues).
ttp://dx.doi.org/10.1016/j.rppnen.2016.02.010
173-5115/© 2016 Sociedade Portuguesa de Pneumologia. Published by 
Y-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/) de Cirurgia Torácica, CHLN-Hospital Pulido Valente. Alameda das
Elsevier Espan˜a, S.L.U. This is an open access article under the CC
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Introduction
Chronic  obstructive  pulmonary  disease  (COPD)  and  lung  can-
cer  are  two  important  causes  of  mortality  and  morbidity
around  the  world.  Lung  cancer  is  a  leading  cause  of  cancer
mortality  in  both  genders.1 It  is  estimated  that  COPD  will
be  the  fourth  worldwide  leading  cause  of  death  in  2030.2
Since  these  two  diseases  occur  frequently  associated,  it  is
expected  that  they  will  be  major  causes  of  death  in  devel-
oped  countries.3
The  most  powerful  therapeutic  approach  for  non-small
cell  lung  carcinoma  is  lung  surgical  resection.4 However,
this  option  is  associated  with  higher  morbidity  and  mortality
in  patients  with  low  ventilatory  reserve,  which  is  a  com-
mon  limiting  factor  for  lung  cancer  surgery  in  patients  with
COPD.5,6 In  this  way,  preoperative  risk  assessment  should
be  performed  to  achieve  an  accurate  risk  stratiﬁcation.
Many  parameters  have  been  proposed  as  predictors  of  peri-
operative  risk.  They  include  clinical  parameters:  smoking,
cough,  wheeze,  bronchorrhea  and  comorbidities,  mainly
cardiovascular7;  functional  parameters  at  rest:  forced  expi-
ratory  volume  in  the  ﬁrst  second  (FEV1)  and  diffusing
capacity  of  the  lung  for  carbon  monoxide  (DLCO);  predicted
postoperative  FEV1 (ppoFEV1)  and  DLCO  (ppoDLCO)  values
as  well  as,  exercise  tests:  stair  climbing  test,  shuttle  walk
test  and/or  cardiopulmonary  exercise  test  (CPET)  on  cycle
ergometer  or  treadmill.8 Exercise  testing  has  been  consid-
ered  a  better  predictor  of  postoperative  complications  than
rest  evaluations  and  the  CPET  is  the  gold  standard.  This  test
assesses  the  physiological  reserve  at  maximal  exertion  and,
in  this  way,  mimics  the  response  to  surgical  stress  or  adverse
post-operative  events.8
In  CPET,  peak  oxygen  uptake  (VO2peak)  is  the  single
most  important  parameter  in  the  assessment  of  the  surgery
risk,  with  values  above  20  mL/kg/min  or  75%  of  pre-
dicted  being  indicated  as  the  limits  for  an  acceptable
risk  for  pneumonectomy.9 Although  VO2peak values  between
10--20  mL/kg/min  and/or  35--75%  of  predicted  also  allow
lung  resection  surgery,  it  is  necessary  to  evaluate  with
higher  accuracy  the  risk  of  surgery  within  those  intervals.
As  an  example,  Smith  and  Data  proposed  the  cut-off  VO2peak
15  mL/kg/min.10,11
Our  study  was  carried  out  to  assess  factors  associated
with  cardiopulmonary  complications  within  30  days  after
tumor  resection  surgery,  in  a  cohort  of  patients  with  COPD
and  lung  cancer  assigned  to  perform  a  CPET.
Methods
Subjects
In  the  period  between  1997  and  2012,  a  historical  cohort
of  50  consecutive  patients  with  COPD  and  potentially
resectable  lung  cancer  were  referred  to  perform  CPET  for
risk  stratiﬁcation  evaluation  and  afterwards  were  subject
to  tumor  resection  surgery  at  Servic¸o de  Cirurgia  Torá-
cica,  Hospital  Pulido  Valente,  Lisbon,  Portugal.  The  sample
included  all  COPD  patients  considered  to  be  at  high  surgical
risk  by  their  assistant  surgeon.  Criteria  were  clinical  car-
diopulmonary  risk  factors,  such  as  being  a  current  smoker,
presenting  bronchorrhea,  dyspnea,  exercise  intolerance  and
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elevant  comorbidities,  including  cardiac,  cerebrovascular
nd  metabolic  diseases;  and/or  respiratory  functional  limi-
ation:  FEV1 and/or  DLCO  below  60%  predicted.11--13 Patients
ere  characterized  by  age,  gender,  smoking  history,  comor-
idities,  lung  cancer  histology,  neoadjuvant  chemotherapy,
xtent  of  lung  resection  and  cardiopulmonary  complications
ithin  30  days  after  surgery.  All  subjects’  clinical  data  were
btained  from  the  medical  records.
The  hospital’s  ethics  committee  and  administration
oard  approved  the  conduction  of  the  trial  (IRB:  DIRCLIN-
2.NOV.2014-0487).
ung  function  study
pirometry  and  diffusion  capacity  study  were  performed
ccording  to  guidelines,14,15 as  well  as  arterial  blood  gas
amples.  Predicted  postoperative  values  for  FEV1 and  DLCO
ere  calculated  according  to  the  segment  method  (based  on
he  proportion  of  open  and  functional  lung  segments  to  be
emoved).9,16
ardiopulmonary  exercise  test
atients  underwent  a  symptom-limited  cycle  ergometry,
ollowing  Wasserman  et  al.17 and  American  Thoracic  Soci-
ty/American  College  of  Chest  Physicians  statement.18 The
O2peak value  was  recorded  in  L/min,  mL/kg/min  and  as  a
ercentage  of  predicted  normal  values  according  to  Jones
nd  Hansen  equations.19,20
ulmonary  rehabilitation
ll  patients  followed  a  postoperative  pulmonary  rehabili-
ation  program  that  included  lung  expansion  techniques,
ain  control  and  exercise  training.  Whenever  possible,  a
reoperative  intervention  was  also  implemented,  including
moking  cessation  interventions,  respiratory  physiotherapy,
nd  exercise  training.21
tatistical  analysis
n  exploratory  analysis  was  performed  for  all  variables.
ategorical  data  were  presented  as  frequencies  and  per-
entages,  and  continuous  variables  were  presented  as  mean
r  median,  standard  deviation  (SD),  or  interquartile  range
IQR:  25th  percentile--75th  percentile)  as  appropriate.
The  entire  group  was  divided  into  patients  with  and
ithout  cardiopulmonary  complications  within  30  days  after
urgery.  To  compare  sociodemographic,  clinical,  as  well  as
est  and  exercise  functional  data  between  the  two  groups,
tudent’s  t  test  and  non-parametric  tests  (Chi-square  test,
isher’s  exact  test,  Mann--Whitney  U  test)  were  employed.
To  categorize  VO2peak levels,  the  minimum  p-value
pproach  was  used,  which  provides  the  point  from  a  grid
f  marker  values  that  is  associated  with  the  minimum  Chi-
quared  p-value.22 To  evaluate  the  association  between
O2peak and  ppoFEV1, the  nonparametric  smoother  LOWESS
Locally  Weighted  Scatterplot  Smoother)  was  used.
The  95%  conﬁdence  intervals  (CI)  were  calculated  when-
ver  appropriate.  A  signiﬁcance  level  ˛  =  5%  was  considered.
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Table  1  Clinical  and  demographic  data  in  the  patients  with  and  without  cardiopulmonary  complications  within  30  days  after
tumor resection  surgery  (n  =  50).
All  (n  =  50) With
complications
(n  =  18)
Without
complications
(n  =  32)
p
Gender:  M  (%)/F  (%)  46  (92)/4  (8)  16  (89)/2  (11)  30  (94)/2  (6)  0.612
Age (years)
mean  (SD)  [min--max]
64.7  (7.9)
[46--80]
64.1  (7.0)
[52--78]
65.0  (8.5)
[46--80]
0.680
BMI
mean (SD)  [min--max]
25.6  (4.8)
[14--36]
25.5  (4.9)
[17--35]
25.7  (4.8)
[14--36]
0.878
Pack-years
mean (SD)  [min--max]
68.6  (32.3)
[0--200]
63.5  (27.3)
[0--120]
71.5  (34.9)
[29--200]
0.406
Comorbidities
Hypertension,  n  (%)  19  (38)  9  (50)  10  (31)  0.233
Ischemic cardiopathy,  n  (%)  6  (12)  2  (11)  4  (13)  1.000
Cerebrovascular  disease,  n
(%)
3  (6)  2  (11)  1  (3)  0.291
Other cancer,  n  (%)  6  (12)  1  (6)  5  (16)  0.399
Neoadjuvant  CTx,  n  (%)  10  (20)  6  (33)  4  (13)  0.138
Previous lung  resection,  n  (%)  4  (8)  2  (11)  2  (6)  0.612
Lung resection:
≤lobectomy/>lobectomy,  n
(%)
34  (68)/16  (32)  14  (78)/4  (22)  20  (63)/12  (38)  0.351
Histology:
adenocarcinoma/squamous-
cell carcinoma/others,  n
(%)
22  (44)/19  (38)/9
(18)
6  (33)/9  (50)/3
(17)
16  (50)/10  (31)/6
(19)
0.402
Length of  stay  (days)
median  [IQR]
12.0
[9.0--21.0]
21.0
[12.0--27.5]
10.0
[8.25--13.0]
0.001
M: male; F: female; BMI: body mass index; CTx: chemotherapy; IQR: 25th percentile--75th percentile; max: maximum; min: minimum;
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ll  data  were  analyzed  using  the  Statistical  Package  for
he  Social  Sciences  for  Windows  21.0  (IMB  Corp.  Released
012.  IBM  SPSS  Statistics  for  Windows.  Armonk,  NY:  IBM
orporation)  and  the  R  software  [R:  A  Language  and  Environ-
ent  for  Statistical  Computing,  R  Core  Team,  R  Foundation
or  Statistical  Computing,  Vienna,  Austria,  year  =  2014,
ttp://www.R-project.org].
esults
uring  the  period  studied,  a  total  of  1674  lung  resection
urgeries  for  lung  cancer  were  performed.  This  included
0  COPD  patients  who  performed  CPET  based  on  clinical
r  functional  criteria.  Forty-six  patients  (92.0%)  were  male
ith  a  mean  age  of  64.7  years  (SD  7.9)  (range:  46--80
ears).  The  most  common  comorbidities  were  arterial  hyper-
ension  (19  patients,  38.0%),  ischemic  heart  disease  (6
atients,  12.0%),  other  neoplasm  (6  patients,  12.0%)  and
erebrovascular  disease  (3  patients,  6.0%)  (Table  1).  Twenty-
ve  patients  (50.0%)  were  still  smoking  one  month  before
urgery.The  mean  FEV1 was  1.73  L/min  (SD:  0.50;  ranging  from
.91  to  3.04  L/min)  which  corresponded  to  61.8%  of  pre-
icted  (SD:  9.0%;  33--106%).  DLCO  was  evaluated  in  21
atients  with  a  mean  of  46.0%  (SD:  14.8%;  27--71%).  Of
s
t
nll  patients,  36  (72.0%)  had  FEV1 and/or  DLCO  below  60%.
he  mean  ppoFEV1 was  42.7%  (SD:  14.1;  22--88%)  and  mean
poDLCO  was  30.4%  (SD:  11.3;  11--52%).
Thirty-ﬁve  patients  (70.0%)  underwent  lobectomy  or
ilobectomy,  11  pneumonectomy  (22.0%)  and  4  (8.0%)  wedge
ung  resection.
Eighteen  patients  (36.0%)  had  one  or  more  cardiopul-
onary  complications  within  30  days  after  tumor  resection
urgery,  including  2  deaths  (4.0%).  The  most  frequent
omplications  were  pneumonia  (n  =  7;  38.9%),  dysrhyth-
ia  (n  =  7;  38.9%)  and  total  lung  atelectasis  (n  =  5;  27.8%),
s  shown  in  Fig.  1A.  Death  occurred  in  two  patients
ubmitted  to  lobectomy  and  bilobectomy,  attributed  to  post-
perative  pneumonia  requiring  invasive  ventilation.  Fig.  1B
ummarizes  sociodemographic,  clinical  and  functional  char-
cteristics  of  the  deceased  patients.  The  rate  of  pneumonia
ortality  was  28.7%.
The  mean  length  of  stay  was  15  days  (SD:  8;  5--36
ays),  being  statistically  signiﬁcant  longer  in  the  group  with
omplications  (20.3;  SD:  8.4  versus  12.1;  SD:  6.4  days,
 < 0.001).
There  was  no  statistically  signiﬁcant  difference  inociodemographic  and  clinical  variables  evaluated  within
he  groups  with  and  without  complications  (Table  1).
Likewise,  pulmonary  function  at  rest  did  not  evidence  sig-
iﬁcantly  differences  between  the  groups  (Table  2).  There
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Figure  1  (A)  Cardiorespiratory  complications  within  30  days  after  tumor  resection  surgery.  (B)  Clinical,  demographic  and  functional
data of  patients  who  died.  *Current  smoker.  BMI:  body  mass  index;  FEV1:  forced  expiratory  volume  in  the  ﬁrst  second;  ppoFEV1:
predicted postoperative  value  for  FEV1;  DLCO:  carbon  monoxide  diffusing  capacity;  DLCO/VA:  DLCO  corrected  to  alveolar  volume;
ppoDLCO: predicted  postoperative  value  for  DLCO;  PaO2:  partial  pressure  of  arterial  oxygen;  PaCO2:  partial  pressure  of  arterial
carbon dioxide;  VO2peak:  peak  oxygen  uptake.
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Figure  3  Cut-off  point  value  of  VO2 peak,  mL/kg/min  (61%)  dis-
tinguished  patients’  group  with  higher  number  of  complications
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pFigure  2  Association  between  VO2peak,  mL/kg/min  (%)  and
ppoFEV1 (%  predicted  value).
was  no  direct  association  between  ppoFEV1 and  VO2peak.
As  shown  in  Fig.  2,  patients  with  lower  ppoFEV1 values
(between  22.1%  and  38.7%)  had  a  wide  range  of  VO2peak
values  (46--100%).There  was  a  statistically  signiﬁcant  difference  in  VO2peak
value  when  it  was  expressed  in  percentage  of  predicted
mL/kg/min  value  (59.5  versus  66.5%)  and  L/min  (50.0  versus
57.0%),  between  patients  with  and  without  complications
(
7
mersus  those  with  less  complications  (67%  versus  33%)  (OR:  5.1
1.5; 17.8],  p  =  0.010).
Table  2).  The  achieved  cut-off  point  which  deﬁned  the
roup  with  higher  number  of  complications  was  61.0%
Fig.  3).  Among  patients  with  complications,  12  (66.7%)  had
O2peak (mL/kg/min)  below  or  equal  to  61.0%  and  only  6
33.3%)  had  values  above  this  cut-off  [OR:  5.1  (1.5;  17.8),
 =  0.010].
In  relation  to  the  VO2peak absolute  values,  ﬁfteen  patients30.0%)  had  VO2peak lower  than  15  mL/kg/min,  from  whom,
 (46.7%)  had  one  or  more  complications,  however,  without
ortality.  In  this  sample,  VO2peak cut-off  of  15  mL/kg/min  did
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Table  2  Lung  function  study  at  rest  and  cardiopulmonary  exercise  test  in  patients  with  and  without  cardiopulmonary
complications  within  30  days  after  tumor  resection  surgery  (n  =  50).
All  (n  =  50) With
complications
(n  =  18)
Without
complications
(n  =  32)
p
Lung  function  study
FVC  (L)
mean  (SD)  [min--max]
3.33  (0.82)
[1.80--5.10]
3.40  (0.80)
[2.10--5.10]
3.28  (0.84)
[1.80--5.10]
0.777
FVC (%)
mean  (SD)  [min--max]
93.7  (18.9)
[57--146]
96.6  (17.1)
[68--131]
92.1  (20.0)
[57--146]
0.352
FEV1 (L)
mean  (SD)  [min--max]
1.73  (0.50)
[0.91--3.04]
1.76  (0.43)
[1.20--2.60]
1.71  (0.53)
[0.90--3.00]
0.518
FEV1 (%)
mean  (SD)  [min--max]
61.8  (19.0)
[33--106]
64.3  (17.2)
[39--106]
60.4  (20.1)
[33--101]
0.374
ppoFEV1 (%)
mean  (SD)  [min--max]
42.7  (14.1)
[22--88]
46.3  (13.6)
[29--78]
40.7  (14.1)
[22--88]
0.075
FEV1/FVC  (%)
mean  (SD)  [min--max]
51.7  (10.4)
[27--69]
52.5  (9.2)
[35--67]
51.2  (11.1)
[27--69]
0.701
DLCO (%)
mean  (SD)  [min--max]
46.0  (14.8)
[27--71]
44.3  (16.3)
[27--71]a
47.5  (13.9)
[27--65]b
0.572
DLCO/VA (%)
mean  (SD)  [min--max]
48.1  (17.2)
[30--80]
47.3  (17.4)
[32--78]a
48.7  (17.8)
[30--80]b
0.860
ppoDLCO (%)
mean  (SD)  [min--max]
30.4  (11.3)
[11--52]
29.6  (13.4)
[11--52]a
31.0  (9.6)
[17--45]b
0.751
PaO2 (mmHg)
mean  (SD)  [min--max]
74.77  (9.25)
[48.80--99.00]
76.41  (10.07)
[54.80--99.00]
73.85  (8.79)
[48.80--95.50]
0.374
PaCO2 (mmHg)
mean  (SD)  [min--max]
39.34  (3.82)
[28.90--47.50]
38.53  (3.73)
[28.90--45.40]
39.79  (3.85)
[29.60--47.50]
0.169
Cardiopulmonary  exercise  test
VO2peak (L/min)
median  [IQR]
1.15  [1.00--1.35]  1.06  [0.87--1.33]  1.17  [1.10--1.36]  0.086
VO2peak (L/min)  (%)
median  [IQR]
54.5  [47--62]  50.0  [44--57]  57.0  [49--68]  0.046
VO2peak (mL/kg/min)
median  [IQR]
16.50
[14.25--17.68]
16.15
[12.90--17.40]
16.65
[14.78--17.83]
0.206
VO2peak (mL/kg/min)  (%)
median  [IQR]
65.0  [56--75] 59.5  [52--69] 66.5  [60--85] 0.027
Wmax (watts)
median  [IQR]
69.0  [59.0--89.0]  73.5  [57.8--87.5]  69.0  [59.0--89.8]  0.723
Wmax (%)
median  [IQR]
52.0  [42--62]  57.0  [47--63]c 49.0  [42--64]d 0.363
FVC: forced vital capacity; FEV1: forced expiratory volume in the ﬁrst second; ppoFEV1: predicted postoperative value for FEV1; DLCO:
carbon monoxide diffusing capacity; DLCO/VA: DLCO corrected to alveolar volume; ppoDLCO: predicted postoperative value for DLCO;
PaO2: partial pressure of arterial oxygen; PaCO2: partial pressure of arterial carbon dioxide; VO2peak: peak oxygen uptake; W: work rate.
IQR: 25th percentile--75th percentile; max: maximum; min: minimum; SD: standard deviation.
a n = 10.
b n = 11.
n
(
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cc n = 16.
d n = 31.
ot  distinguish  the  patients  with  or  without  complications
p  = 0.304).  In  contrast  to  VO2peak expressed  in  percentage  of
ormal  values,  the  difference  documented  in  VO2peak abso-
ute  value  did  not  show  statistical  signiﬁcance  (Table  2).iscussion
his  study  highlights  the  relevance  of  CPET  in  the  risk  strat-
ﬁcation  of  lung  cancer  resection  surgery  in  patients  with
i
h
p
lOPD.  Among  these  high  risk  patients,  VO2peak was  the  only
arameter  associated  to  postoperative  complications,  which
s  consistent  with  other  studies.9,10,12,23
The  present  study  underlines  the  VO2peak expressed  in
ercentage  of  predicted  normal  values  and  indicates  the
ut-off  of  61.0%  below  which,  there  was  a  signiﬁcant
ncrease  of  postoperative  complications.  Other  authors  also
ighlight  VO2peak percentage  of  predicted  values  as  a  better
redictor  of  postoperative  complications  than  the  abso-
ute  values.  The  latter  does  not  take  gender,  age  and
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height  into  account.12,23 Bolliger  et  al.  proposed  the  cut-
off  value  below  60%  of  predicted  as  being  highly  predictive
of  complications.12 They  also  considered  that  values  of
VO2peak above  75%  of  predicted  values  indicate  low  risk  of
complications,  regardless  of  the  extent  of  lung  resection.
Win  et  al.  suggested  a  VO2peak threshold  of  50--60%  of  pre-
dicted  as  an  acceptable  indication  for  lung  resection.23
Cut-off  values  of  VO2peak expressed  in  mL/kg/min  have
also  been  suggested.  Thus,  VO2peak above  20  mL/kg/min
have  been  indicated  as  the  limits  for  acceptable  risk  for
pneumonectomy9 and  values  below  10  mL/kg/min  as  very
high  risk  for  any  kind  of  lung  resection.8
However,  the  available  scientiﬁc  evidence  is  still  insuf-
ﬁcient  to  deﬁne  the  VO2peak threshold  for  lobectomy.8
Considering  that  in  our  study  most  of  the  resections  (78.0%)
were  less  radical  than  pneumonectomy  (70.0%  lobectomy  or
bilobectomy  and  8.0%  wedge  resections),  we  believe  that
our  data  contributed  to  establish  the  VO2peak threshold  for
the  lobectomy  complications.
Apart  from  discriminative  value  of  the  CPET  for
complications,  it  also  meant  that  in  our  sample  high-risk
patients  (according  to  clinical  and/or  resting  lung  function
parameters)  underwent  curative-intent  lung  cancer  surgery
with  higher  life  expectancy  and  an  acceptable  mortality.  In
fact,  among  the  36  patients  with  FEV1 and/or  DLCO  less  than
60%,  the  CPET  allowed  the  tumor  resection  in  34  patients
(94.4%).
The  results  of  this  study  indicate  that  CPET  is  a  more
reliable  global  assessment  tool  than  lung  function  testing
performed  at  rest.  The  superior  value  of  VO2peak compared
to  ppoFEV1,  is  shown  in  Fig.  2,  where  the  lowest  ppoFEV1
values  were  associated  with  a  wide  range  of  VO2peak values.
The  rate  of  complications  (36.0%)  and  mortality  (4.0%)
were  similar  to  other  authors’  results  --  20--40%  of
complications  and  1.6--7%  of  mortality.24
In  our  study,  the  cause  of  the  two  deaths  was  pneumonia
requiring  invasive  ventilation.  Pneumonia  is  one  of  the  most
common  complications  after  lung  resection  surgery  and,  in
Portugal,  it  is  associated  with  high  intra  hospital  mortality
(20.4%  from  2000  to  2009),25 particularly  in  patients  above
65  years.26
Vaporciyan  et  al.27 showed  that  in  patients  submitted  to
pneumonectomy,  the  incidence  of  pulmonary  complications,
mainly  pneumonia  and  acute  respiratory  distress  syndrome,
was  greater  in  those  who  continued  to  smoke  up  to  one
month  before  surgery.  Arguing  that  the  occurrence  of  pul-
monary  complications  was  associated  with  higher  mortality,
these  authors  suggest  the  implementation  of  interventions
to  prevent  them.  American  College  of  Chest  Physicians21 and
European  Respiratory  Society/European  Society  of  Thoracic
Surgery8 recommend  smoking  cessation  at  the  time  of  lung
cancer  diagnosis  and  for  at  least  2--4  weeks  before  surgery,
as  a  way  of  improving  lung  surgery  outcomes.
The  present  study  underlines  the  importance  of  accu-
rate  lung  cancer  resection  risk  stratiﬁcation  in  patients  with
COPD,  allowing  a  curative-intent  lung  cancer  surgery  with-
out  signiﬁcant  mortality  and  morbidity.  This  study  has  some
limitations  that  need  to  be  addressed.  We  emphasize  the  low
number  of  patients  and  the  unknown  DLCO  value  in  a  large
number  of  patients.  Despite  these  limitations,  the  sample  is
homogenous  according  to  the  two  associated  diseases  (COPD
and  lung  cancer)  and  the  same  team  of  thoracic  surgeons271
erforming  all  surgeries.  These  aspects  decreased  bias  and
ariability  and  assigns  clinical  and  scientiﬁc  interest  to  our
esults.
As  the  criteria  to  perform  CPET  is  a  low  FEV1 and/or
ow  DLCO,  which  was  present  in  the  majority  of  our  sam-
le  data  (72%),  these  might  have  biased  the  association  of
ung  function  at  rest  (FEV1 and  DLCO)  and  the  complications,
ot  showing  a  signiﬁcant  correlation.
onclusion
PET  is  a  valuable  tool  in  the  risk  assessment  of  pulmonary
esection  surgery  in  patients  with  lung  cancer  and  COPD.
mong  these  high-risk  patients,  regarding  clinical  and  func-
ional  parameters,  VO2peak expressed  in  percentage  of  the
redicted  value  was  the  best  discriminator  for  occurrence
f  complications  and  should  be  taken  into  account  in  the
ssessment  of  lung  resection  surgery  risk.
This  study  contributed  to  deﬁne  61%  value  as  the  VO2peak
ut-off  above  which  lung  resection  surgery  risk  is  considered
cceptable  in  patients  with  lung  cancer  and  COPD.
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